Do analysts recommend BYSI or FNCH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is BYSI or FNCH more profitable?

BeyondSpring's return on equity of 0.00% beat Finch Therapeutics Group's return on equity. Company Net Margins Return on Equity Return on Assets BeyondSpring N/A N/A -14.00% Finch Therapeutics Group N/A -69.14% -26.92%

Do analysts prefer FNCH or MREO?

Mereo BioPharma Group has a consensus target price of $3.25, indicating a potential upside of 1,029.26%. Given Mereo BioPharma Group's stronger consensus rating and higher probable upside, analysts plainly believe Mereo BioPharma Group is more favorable than Finch Therapeutics Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Mereo BioPharma Group 1 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is FNCH or MREO more profitable?

Finch Therapeutics Group's return on equity of -69.14% beat Mereo BioPharma Group's return on equity. Company Net Margins Return on Equity Return on Assets Finch Therapeutics Group N/A -69.14% -26.92% Mereo BioPharma Group N/A -81.28% -70.45%

Do analysts recommend MGX or FNCH?

Metagenomi currently has a consensus price target of $7.00, suggesting a potential upside of 480.91%. Given Metagenomi's stronger consensus rating and higher probable upside, research analysts clearly believe Metagenomi is more favorable than Finch Therapeutics Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metagenomi 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend FNCH or INMB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is FNCH or INMB more profitable?

Finch Therapeutics Group's return on equity of -69.14% beat INmune Bio's return on equity. Company Net Margins Return on Equity Return on Assets Finch Therapeutics Group N/A -69.14% -26.92% INmune Bio N/A -103.03% -77.66%

Do analysts prefer FNCH or EXOZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is FNCH or EXOZ more profitable?

Finch Therapeutics Group's return on equity of -69.14% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets Finch Therapeutics Group N/A -69.14% -26.92% eXoZymes N/A -220.63% -141.26%

Finch Therapeutics Group (FNCH) Competitors

$7.30 0.00 (0.00%)

As of 07/24/2026

Compare

FNCH vs. BYSI, MREO, MGX, INMB, and EXOZ

Should you buy Finch Therapeutics Group stock or one of its competitors? MarketBeat compares Finch Therapeutics Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Finch Therapeutics Group include BeyondSpring (BYSI), Mereo BioPharma Group (MREO), Metagenomi (MGX), INmune Bio (INMB), and eXoZymes (EXOZ). These companies are all part of the "pharmaceutical products" industry.

How does Finch Therapeutics Group compare to BeyondSpring?

BeyondSpring (NASDAQ:BYSI) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

BeyondSpring's return on equity of 0.00% beat Finch Therapeutics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-14.00%
Finch Therapeutics Group	N/A	-69.14%	-26.92%

BeyondSpring has higher revenue and earnings than Finch Therapeutics Group. BeyondSpring is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	26.32	-$1.01M	-$0.14	N/A
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A

40.3% of BeyondSpring shares are owned by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are owned by institutional investors. 29.3% of BeyondSpring shares are owned by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, BeyondSpring had 1 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 1 mentions for BeyondSpring and 0 mentions for Finch Therapeutics Group. BeyondSpring's average media sentiment score of 1.89 beat Finch Therapeutics Group's score of 0.00 indicating that BeyondSpring is being referred to more favorably in the media.

Company	Overall Sentiment
BeyondSpring	Very Positive
Finch Therapeutics Group	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

BeyondSpring has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market. Comparatively, Finch Therapeutics Group has a beta of 1.18, indicating that its stock price is 18% more volatile than the broader market.

Summary

BeyondSpring beats Finch Therapeutics Group on 9 of the 12 factors compared between the two stocks.

How does Finch Therapeutics Group compare to Mereo BioPharma Group?

Finch Therapeutics Group (NASDAQ:FNCH) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

In the previous week, Mereo BioPharma Group had 2 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 2 mentions for Mereo BioPharma Group and 0 mentions for Finch Therapeutics Group. Mereo BioPharma Group's average media sentiment score of 1.43 beat Finch Therapeutics Group's score of 0.00 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Finch Therapeutics Group	Neutral
Mereo BioPharma Group	Positive

21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by company insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Finch Therapeutics Group has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

Mereo BioPharma Group has a consensus target price of $3.25, indicating a potential upside of 1,029.26%. Given Mereo BioPharma Group's stronger consensus rating and higher probable upside, analysts plainly believe Mereo BioPharma Group is more favorable than Finch Therapeutics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Mereo BioPharma Group has higher revenue and earnings than Finch Therapeutics Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A
Mereo BioPharma Group	$500K	91.88	-$41.88M	-$0.05	N/A

Finch Therapeutics Group's return on equity of -69.14% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
Mereo BioPharma Group	N/A	-81.28%	-70.45%

Summary

Mereo BioPharma Group beats Finch Therapeutics Group on 9 of the 14 factors compared between the two stocks.

How does Finch Therapeutics Group compare to Metagenomi?

Metagenomi (NASDAQ:MGX) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Finch Therapeutics Group has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat Finch Therapeutics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-51.23%	-36.62%
Finch Therapeutics Group	N/A	-69.14%	-26.92%

Finch Therapeutics Group has lower revenue, but higher earnings than Metagenomi. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.80	-$87.87M	-$2.30	N/A
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A

Metagenomi has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Finch Therapeutics Group has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

21.8% of Finch Therapeutics Group shares are owned by institutional investors. 12.5% of Metagenomi shares are owned by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Metagenomi currently has a consensus price target of $7.00, suggesting a potential upside of 480.91%. Given Metagenomi's stronger consensus rating and higher probable upside, research analysts clearly believe Metagenomi is more favorable than Finch Therapeutics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Metagenomi had 3 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 3 mentions for Metagenomi and 0 mentions for Finch Therapeutics Group. Metagenomi's average media sentiment score of 0.35 beat Finch Therapeutics Group's score of 0.00 indicating that Metagenomi is being referred to more favorably in the media.

Company	Overall Sentiment
Metagenomi	Neutral
Finch Therapeutics Group	Neutral

Summary

Metagenomi beats Finch Therapeutics Group on 10 of the 16 factors compared between the two stocks.

How does Finch Therapeutics Group compare to INmune Bio?

Finch Therapeutics Group (NASDAQ:FNCH) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

In the previous week, INmune Bio had 3 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 3 mentions for INmune Bio and 0 mentions for Finch Therapeutics Group. INmune Bio's average media sentiment score of 0.63 beat Finch Therapeutics Group's score of 0.00 indicating that INmune Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Finch Therapeutics Group	Neutral
INmune Bio	Positive

Finch Therapeutics Group has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, INmune Bio has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

INmune Bio has higher revenue and earnings than Finch Therapeutics Group. INmune Bio is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A
INmune Bio	$50K	861.19	-$45.93M	-$1.67	N/A

21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 12.7% of INmune Bio shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by company insiders. Comparatively, 21.4% of INmune Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Finch Therapeutics Group's return on equity of -69.14% beat INmune Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
INmune Bio	N/A	-103.03%	-77.66%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

INmune Bio beats Finch Therapeutics Group on 7 of the 13 factors compared between the two stocks.

How does Finch Therapeutics Group compare to eXoZymes?

Finch Therapeutics Group (NASDAQ:FNCH) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

In the previous week, eXoZymes had 1 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 1 mentions for eXoZymes and 0 mentions for Finch Therapeutics Group. eXoZymes' average media sentiment score of 0.93 beat Finch Therapeutics Group's score of 0.00 indicating that eXoZymes is being referred to more favorably in the news media.

Company	Overall Sentiment
Finch Therapeutics Group	Neutral
eXoZymes	Positive

eXoZymes has higher revenue and earnings than Finch Therapeutics Group. eXoZymes is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A
eXoZymes	$70K	619.70	-$9.16M	-$1.14	N/A

Finch Therapeutics Group's return on equity of -69.14% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-69.14%	-26.92%
eXoZymes	N/A	-220.63%	-141.26%

Finch Therapeutics Group has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market. Comparatively, eXoZymes has a beta of 2.73, suggesting that its share price is 173% more volatile than the broader market.

21.8% of Finch Therapeutics Group shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by insiders. Comparatively, 72.4% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

eXoZymes beats Finch Therapeutics Group on 8 of the 12 factors compared between the two stocks.

Get Finch Therapeutics Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FNCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FNCH vs. The Competition

Export

Metric	Finch Therapeutics Group	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$11.72M	$357.18M	$7.07B	$12.21B
Dividend Yield	N/A	N/A	2.67%	9.80%
P/E Ratio	-0.83	N/A	27.14	23.61
Price / Sales	N/A	228.84	523.34	90.24
Price / Cash	N/A	22.44	26.39	46.67
Price / Book	0.51	4.88	10.30	6.08
Net Income	-$74.75M	-$141.03M	$3.60B	$331.70M
7 Day Performance	N/A	-1.69%	-1.27%	-0.63%
1 Month Performance	N/A	-3.98%	-1.67%	-3.04%
1 Year Performance	-41.83%	41.50%	18.25%	13.30%

Finch Therapeutics Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FNCH Finch Therapeutics Group	N/A	$7.30 flat	N/A	N/A	$11.72M	N/A	N/A	190
BYSI BeyondSpring	0.1668 of 5 stars	$1.13 +4.2%	N/A	-41.7%	$46.26M	$1.75M	N/A	80
MREO Mereo BioPharma Group	3.16 of 5 stars	$0.29 flat	$3.25 +1,016.8%	-83.6%	$46.13M	$500K	N/A	40	Positive News Short Interest Decrease
MGX Metagenomi	3.8845 of 5 stars	$1.21 -1.2%	$7.00 +480.9%	-50.4%	$45.37M	$25.21M	N/A	236	Analyst Downgrade
INMB INmune Bio	1.028 of 5 stars	$1.68 -2.3%	N/A	-40.2%	$44.79M	$50K	N/A	10	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FNCH) was last updated on 7/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Finch Therapeutics Group (FNCH) Competitors

FNCH vs. BYSI, MREO, MGX, INMB, and EXOZ

How does Finch Therapeutics Group compare to BeyondSpring?

Summary

How does Finch Therapeutics Group compare to Mereo BioPharma Group?

Summary

How does Finch Therapeutics Group compare to Metagenomi?

Summary

How does Finch Therapeutics Group compare to INmune Bio?

Summary

How does Finch Therapeutics Group compare to eXoZymes?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FNCH vs. The Competition

Finch Therapeutics Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Finch Therapeutics Group (FNCH) Competitors

FNCH vs. BYSI, MREO, MGX, INMB, and EXOZ

How does Finch Therapeutics Group compare to BeyondSpring?

Is BYSI or FNCH more profitable?

Which has preferable valuation & earnings, BYSI or FNCH?

Do insiders and institutionals have more ownership in BYSI or FNCH?

Does the media refer more to BYSI or FNCH?

Do analysts recommend BYSI or FNCH?

Which has more volatility and risk, BYSI or FNCH?

Summary

How does Finch Therapeutics Group compare to Mereo BioPharma Group?

Does the media prefer FNCH or MREO?

Do institutionals and insiders believe in FNCH or MREO?

Which has more volatility & risk, FNCH or MREO?

Do analysts prefer FNCH or MREO?

Which has stronger earnings & valuation, FNCH or MREO?

Is FNCH or MREO more profitable?

Summary

How does Finch Therapeutics Group compare to Metagenomi?

Is MGX or FNCH more profitable?

Which has preferable earnings and valuation, MGX or FNCH?

Which has more volatility & risk, MGX or FNCH?

Do institutionals & insiders have more ownership in MGX or FNCH?

Do analysts recommend MGX or FNCH?

Does the media favor MGX or FNCH?

Summary

How does Finch Therapeutics Group compare to INmune Bio?

Does the media refer more to FNCH or INMB?

Which has more risk and volatility, FNCH or INMB?

Which has preferable earnings and valuation, FNCH or INMB?

Do insiders & institutionals have more ownership in FNCH or INMB?

Is FNCH or INMB more profitable?

Do analysts recommend FNCH or INMB?

Summary

How does Finch Therapeutics Group compare to eXoZymes?

Does the media favor FNCH or EXOZ?

Which has stronger earnings and valuation, FNCH or EXOZ?

Is FNCH or EXOZ more profitable?

Which has more volatility & risk, FNCH or EXOZ?

Do insiders & institutionals hold more shares of FNCH or EXOZ?

Do analysts prefer FNCH or EXOZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FNCH vs. The Competition

Finch Therapeutics Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools